

References

I-78

1. Boyer DS, Yoon TH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. *Ophthalmology*. 2014;121(10):1904-14
2. Cutino AC, Kendall R, Zachary C. Economic evaluation of a fluocinolone acetonide intravitreal implant for patients with DME based on the FAME study. *Am J Managed Care*. 2015;21(4):S61-S73.
3. Kuppermann BD, Goldstein M, Maturi RK, et al. Dexamethasone intravitreal implant as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration: A multicenter randomized controlled trial. *Ophthalmologica*. 2015; 234(1):40-54.
4. Caillaux V, Souied EH, Valtot F, Mimoun G. Intraocular pressure after intravitreal injection of dexamethasone implant for macular edema resulting from retinal vein occlusion. *Eur J Ophthalmol*. 2015; 25(5): 454-458.
5. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: Long-term benefit in patients with chronic diabetic macular edema. *Ophthalmology*. 2014;121(10):1892-1903.
6. Ynag Y, Baily C, Holz FG, et al. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAC) implants. *Eye(Lond)*. 2015;29(9):1173-1180.
7. National Institute for Health and Care Excellence (NICE). Dexamethasone intravitreal implant for treating diabetic macular edema. 2015.
8. Freitas-Neto C, Maghsoudlou A, Foster C, et al. Outcome of multiple implants and dissociation of fluocinolone acetonide intravitreal implant (Retisert) in a series of 187 consecutive implants. *Ocular Immunology and Inflammation*. 2015;23(6):425-429.
9. Ragam A, Kolomeyer A, Nayak N, Chu D. The use of Ozurdex (dexamethasone intravitreal implant) during anterior segment surgery in patients with chronic recurrent uveitis. *The Official Journal Of The Association For Ocular Pharmacology and Therapeutics*. 2015;31(6):344-349.
10. Illuvien® (fluocinolone acetonide intravitreal implant) [package insert]. Alimera Sciences, Inc.; Alpharetta, GA. 1963, revised 11/2016.
11. Ozurdex™ (dexamethasone intravitreal implant) [package insert]. Allergan, Inc.; Irvine, CA. 09/2010, revised 05/2018.
12. Retisert® (fluocinolone acetonide intravitreal implant) [package insert]. Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC; Bridgewater, NJ. 1963, revised 12/2017.
13. Yutiq™ (fluocinolone acetonide intravitreal implant) [package insert]. EyePoint Pharmaceuticals; Watertown, MA. 1963, revised 10/2018.
14. Hayes Inc. Health Technology Assessment. Dexamethasone Intravitreal Implant (Ozurdex; Allergan Inc.) for Treatment of Diabetic Macular Edema. December 10, 2018. Accessed June 26, 2019.

15. Hayes Inc. Health Technology Assessment. Dexamethasone Intravitreal Implant (Ozurdex; Allergan Inc.) for Treatment of Retinal Vein Occlusion. March 9, 2017. Accessed June 26, 2019.
16. Patil L, Lotery AJ. Coat's-like exudation in rhodopsin retinitis pigmentosa: Successful treatment with an intravitreal dexamethasone implant. *Eye (Lond)*. 2014;28(4):449-451.
17. Ahn SJ, Kim KE, Woo SJ, et al. The effect of an intravitreal dexamethasone implant for cystoid macular edema in retinitis pigmentosa: A case report and literature review. *Ophthalmic Surg Lasers Imaging Retina*. 2014;45(2):160-164.
18. Gillespie BW, Musch DC, Niziol LM, et al. Estimating minimally important differences for two vision specific quality of life measures. *Invest Ophthalmol Vis Sci*. 2014;55(7):4206-4212.
19. Loutfi M, Papathomas T, Kamal A. Macular oedema related to idiopathic macular telangiectasia type 1 treated with dexamethasone intravitreal implant (ozurdex). *Case Rep Ophthalmol Med*. 2014;2014:231913.
20. Maturi RK, Chen V, Raghinaru D, et al. A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion. *Clin Ophthalmol*. 2014;8:1057-1064.
21. Multicenter Uveitis Steroid Treatment Trial Research Group. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: Fifty-four-month results of the Multicenter Uveitis Steroid Treatment (MUST) trial and follow-up study. *Ophthalmology*. 2015;122(10):1967-1975.
22. Multicenter Uveitis Steroid Treatment Trial Follow-up Study Research Group. Quality of life and risks associated with systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, or panuveitis: Fifty-four-month results of the Multicenter Uveitis Steroid Treatment trial and follow-up study. *Ophthalmology*. 2015;122(10):1976-1986.
23. Brady CJ, Villanti AC, Law HA, et al. Corticosteroid implants for chronic non-infectious uveitis. *Cochrane Database Syst Rev*. 2016;2:CD010469.
24. Holbrook JT, Sugar EA, Burke AE, et al. Dissociations of the fluocinolone acetonide implant: The Multicenter Uveitis Steroid Treatment (MUST) trial and follow-up study. *Am J Ophthalmol*. 2016;164:29-36.
25. Massin P, Erginay A, Dupas B, et al. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: A real-life study. *Clin Ophthalmol*. 2016;10:1257-1264.
26. Ornek N, Ornek K, Erbahceci IE. Intravitreal dexamethasone implant (Ozurdex) for refractory macular edema secondary to retinitis pigmentosa. *Turk J Ophthalmol*. 2016;46(4):179-181.
27. Sudhalkar A, Chhablani J, Vasavada A, et al. Intravitreal dexamethasone implant for recurrent cystoid macular edema due to Irvine-Gass syndrome: a prospective case series. *Eye (Lond)*. 2016;30(12):1549-1557.